SC 13G: Inhibikase Therapeutics, Inc.

AI Summary

SC 13G filing by Inhibikase Therapeutics, Inc..

Risk Assessment

Risk Level: low

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti

Filing Documents

• d858428dsc13g.htm (SC 13G) — 46KB
• d858428dex991.htm (EX-99.1) — 4KB
• 0001193125-24-245696.txt ( ) — 52KB

From the Filing

SC 13G 1 d858428dsc13g.htm SC 13G SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Amendment No )* Under the Securities Exchange Act of 1934 INHIBIKASE THERAPEUTICS INC (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45719W205 (CUSIP Number) October 21, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 1. NAMES OF REPORTING PERSONS SP IKT HOLDINGS LLC I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY): 83-18418459 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)(b) 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 5,840,000 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 5,840,000 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,840,000 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.69% 12. TYPE OF REPORTING PERSON (See Instructions) OO 1. NAMES OF REPORTING PERSONS SP Soleus Holdings LLC I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY): 83-1818459 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)(b) 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 5,840,000 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 5,840,000 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,840,000 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.69% 12. TYPE OF REPORTING PERSON (See Instructions) OO Item1. (a) Name of Issuer Inhibikase Therapeutics, Inc. (the Issuer) (b) Address of Issuers Principal Executive Offices 3350 Riverwood Parkway SE, Suite 1900 Atlanta, GA 30339 Item2. (a) Name of Person Filing This statement is filed on behalf of SP IKT Holdings LLC and SP Soleus Holdings LLC (each, a Reporting Person). (b) Address of Principal Business Office, or if none, Residence The address of the principal business office of each of the Reporting Persons is 20 Horseneck Ln. Greenwich, CT 06880 (c) Citizenship Each of the Reporting Persons is a limited liability company organized under the laws of the State of Delaware. (d) Title of Class of Securities Common Stock, par value $0.001 per share (Common Stock) (e) CUSIP Number 45719W205 Item3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d.2(b) or (c), check whether the person filing is a: Not Applicable. Item4. The Reporting Persons are either holding companies without operations, or are principally engaged in the business of investment management or making, purchasing, selling and holding investments. SP Soleus Holdings LLC is the sole Member of SP IKT Holdings LLC. SP Soleus Holdings LLC is managed by a four-member board of managers, which currently includes Charles A. Davis, Stephen Friedman, David J. Wermuth and Christopher Timchak. Action by the board of managers is by simple majority vote. No individual manager on the board of managers has voting or dispositive control over the reported securities and, therefore, no individual manager has or shares beneficial ownership of such securities and this Statement shall not be construed as an admission of beneficial ownership that any individual manager of the Reporting Person is a beneficial owner of any of the securities covered by this Statement. The ownership percentages reported in this Statement are based on (i) 67,192,570 shares of Common Stock outstanding as of October 21, 2024, as reported by the Issuer pursuant to that certain Schedule 14F-1 filed on October 11, 2024 (giving effect to 58,310,000 shares of Common Stock sold by the Issuer pursuant to a securities purchase agreement, dated October 9, 2024, as reported by the Issuer in its Curre

View Full Filing

View this SC 13G filing on SEC EDGAR